Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PARP1 CRISPR Activation Plasmid (h): sc-400046-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PARP1 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- PARP1 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by PARP1 CRISPR Activation Plasmid (h) and PARP1 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the PARP1 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PARP1 Antibody (F-2): sc-8007
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PARP1 CRISPR Activation Plasmid (h) | sc-400046-ACT | 20 µg | $397.00 |
PARP1 encodes poly(ADP-ribose) polymerase 1, a nuclear DNA damage sensor that catalyzes PARylation of itself and other chromatin-associated proteins to coordinate DNA repair. PARP1 functions prominently in base excision repair and single-strand break repair, and it also influences chromatin remodeling, replication fork stability, and transcriptional regulation through interactions with histones and repair scaffolds. Through crosstalk with ATM/ATR signaling and broader genome maintenance networks, PARP1 helps preserve genomic integrity under oxidative and replication stress. Dysregulated PARP1 activity and altered DNA repair capacity are frequently associated with genomic instability phenotypes observed across multiple cancer contexts and with neurodegeneration-relevant stress responses, supporting its use as a mechanistic target in DNA repair research.
PARP1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous PARP1 expression without altering the underlying DNA sequence.
PARP1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the PARP1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the PARP1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous PARP1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native PARP1 locus and enabling the study of PARP1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of PARP1 pathway restoration in tumor cells with silenced or reduced PARP1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.